Biogen Taps Science Maven Dr. Freire as Chair for Pivotal R&D Push

CAMBRIDGE, Mass. – February 11, 2026 – Biogen Inc. announced a significant leadership transition today, electing Dr. Maria C. Freire to succeed Caroline Dorsa as Chair of the Board of Directors. The change, effective after the company's annual meeting on June 9, 2026, comes as the biotechnology pioneer navigates what it calls a "pivotal moment" and enters a "catalyst-rich period" expected to define its future growth.

Ms. Dorsa will retire after a distinguished 16-year tenure on the board, leaving at a time when the company is intensely focused on executing a renewed strategy under CEO Christopher A. Viehbacher. Dr. Freire, a board member since 2021, brings a formidable background in biomedical innovation and drug development, a profile that appears tailor-made for Biogen's current strategic priorities.

A Strategic Pivot to Scientific Leadership

The appointment of Dr. Freire is widely seen as a deliberate move to align board leadership directly with the company's most critical objective: advancing its late-stage pipeline. Biogen is betting heavily on a series of upcoming clinical and regulatory milestones to offset revenue erosion from its legacy multiple sclerosis franchise and drive a new era of growth.

In her own statement, Dr. Freire acknowledged this crucial phase. "We are embarking on a new chapter for Biogen, having established a robust foundation for sustainable growth and entering a catalyst-rich period with several readouts in the next 18 months, including potentially enabling filing in lupus and nephrology," she said.

This pipeline is indeed robust. The company is developing what it hopes will be an industry-first lupus portfolio, headlined by litifilimab. With promising Phase 2 data in both Systemic and Cutaneous Lupus Erythematosus and an FDA Breakthrough Therapy Designation, its Phase 3 readouts anticipated in the fourth quarter of 2026 are among the most watched events on Biogen's calendar. Further strengthening this focus is dapirolizumab pegol for SLE, developed with UCB, which already has one positive Phase 3 study under its belt. Dr. Freire's deep experience guiding compounds through complex development pathways will be invaluable as these assets approach the finish line.

Beyond lupus, other major catalysts loom. The subcutaneous formulation of its Alzheimer's treatment, LEQEMBI, is under FDA Priority Review with a decision date set for May 24, 2026. A high-dose version of its spinal muscular atrophy drug, SPINRAZA, also awaits an FDA decision by April 3, 2026. Having a chair with a Ph.D. in Biophysics and a career steeped in translational science provides a layer of expert oversight that is critical during such a high-stakes period.

An Orderly Transition and a Veteran's Legacy

The transition appears to be a model of planned succession. Caroline Dorsa, who will not stand for reelection, expressed strong confidence in her successor and the company's direction. "With multiple opportunities ahead, we are at a pivotal moment for the Company, and I believe this is the right time for new Board leadership," Ms. Dorsa stated, adding, "I am confident that the Board will thrive under Maria's leadership."

Ms. Dorsa’s 16-year service provided a steady hand through significant company evolution. Before becoming Chair in June 2023, she served as the long-time Chair of the Audit Committee, a role where she was praised for her financial acumen and integrity. Her tenure as Board Chair, though relatively brief, coincided with the implementation of CEO Chris Viehbacher’s strategic reset, focused on value creation and sustainable growth.

Mr. Viehbacher praised Ms. Dorsa's impact, noting she "fostered a culture of rigor, transparency and trust." He also underscored the strategic fit of her successor. "With Maria’s broad expertise in science and drug development, she is a natural successor to Caroline, bringing important perspective at this pivotal time for Biogen," he said.

A Profile in Biomedical Innovation

Dr. Freire's career represents a masterclass in navigating the intersection of science, business, and public health. Before joining Biogen's board, she served for nearly a decade as the President and Executive Director of the Foundation for the National Institutes of Health (FNIH). There, she led large-scale public-private partnerships to advance research in many of Biogen's core areas, including neurodegenerative diseases and autoimmune disorders.

Her track record in direct drug development is equally impressive. As President and CEO of the Global Alliance for TB Drug Development, she built an organization that successfully advanced the novel drug pretomanid from the preclinical stage through clinical trials. The drug is now approved for treating multidrug-resistant tuberculosis, a testament to her ability to manage capital-efficient development and guide a compound to market.

Her extensive experience also includes serving as Director of the Office of Technology Transfer at the National Institutes of Health, where she managed intellectual property strategy and industry partnerships. This deep understanding of technology commercialization, combined with high-level policy work on the FDA's Science Board and commissions for the World Health Organization and the United Nations, gives her a uniquely holistic view of the life sciences ecosystem. She is also a member of the prestigious National Academy of Medicine and the Council on Foreign Relations.

Guiding Biogen Through a High-Stakes Future

The leadership change comes as Biogen faces a complex landscape. While its new growth products generated $3.3 billion in 2025, the company still projects a revenue decline for 2026 due to competition in its MS business. This reality places immense pressure on its late-stage pipeline to deliver transformative new therapies and revenue streams.

Dr. Freire’s appointment signals the board’s commitment to providing expert, science-led governance to navigate this challenge. Her background is not just a strategic asset for R&D oversight but also for managing the intricate web of regulatory hurdles, pricing pressures, and public health considerations that determine a drug's ultimate success. As the biotech industry increasingly recognizes the need for specialized scientific and policy expertise at the board level, Biogen's choice of Dr. Freire places it at the forefront of this corporate governance trend. Her leadership will be instrumental in determining whether the company's 'new chapter' translates its scientific promise into long-term, sustainable value for both patients and shareholders.